Pfizer (NYSE:PFE) Releases FY 2026 Earnings Guidance

Pfizer (NYSE:PFE) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.800-3.000 for the period, compared to the consensus estimate of 2.970. The company issued revenue guidance of $59.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.3 billion.

Analysts Set New Price Targets

Several research firms have commented on PFE. HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. CICC Research began coverage on Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Finally, Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $28.74.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.07 during midday trading on Wednesday, reaching $26.39. 12,705,651 shares of the company were exchanged, compared to its average volume of 42,566,832. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The stock has a market cap of $150.03 billion, a P/E ratio of 19.44 and a beta of 0.35. Pfizer has a 1 year low of $21.97 and a 1 year high of $28.75. The stock has a fifty day simple moving average of $27.17 and a 200 day simple moving average of $26.13.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the firm earned $0.92 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 beat and reaffirmed full‑year outlook: Pfizer reported Q1 EPS and revenue above consensus and reiterated 2026 guidance, which supported the stock’s lift by signaling execution across core brands and recent acquisitions. Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
• Positive Sentiment: Sales strength from established drugs and new launches: Continued demand for Eliquis and growth from recently launched/acquired products helped drive the beat, easing near‑term revenue concerns as COVID revenue declines. Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Oncology pipeline momentum and FDA nod: FDA approval of VEPPANU (co‑developed with Arvinas) as a first‑in‑class PROTAC for certain breast cancers and positive Phase 3 results for ELREXFIO boost long‑term growth potential and valuation upside if launches scale. Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
• Positive Sentiment: Legal/patent developments improve longer‑term revenue visibility: A Vyndamax patent settlement and favorable legal rulings on vaccine intellectual property were flagged as tailwinds that reshape post‑2028 revenue expectations. Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View
• Neutral Sentiment: Dividend and income appeal: Coverage pieces highlighting Pfizer as a high‑yield dividend stock may support interest from income investors, but they don’t change underlying fundamentals. 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash
• Neutral Sentiment: Earnings call transparency: Full transcripts and call summaries give investors detail on pipeline timelines and capital allocation but are informational rather than catalytic. Pfizer Inc. (NYSE:PFE) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Higher R&D and lower year‑over‑year EPS: Increased R&D spending weighed on profit; Q1 EPS declined versus the prior year, which keeps skeptics cautious about near‑term margin trajectory. Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
• Negative Sentiment: Guidance and skepticism: While guidance was reaffirmed, some analysts note the EPS range and sales outlook leave less upside than investors hoped for, and commentary that the report was “mild” may keep upside muted until pipeline revenues materialize. Why Pfizer’s ‘Mild’ First-Quarter Report Likely Won’t Satisfy Skeptics

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PFE. Morgan Stanley increased its stake in shares of Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Pfizer by 577.5% during the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after purchasing an additional 7,489,189 shares in the last quarter. Amundi grew its stake in Pfizer by 13.4% in the 4th quarter. Amundi now owns 47,063,380 shares of the biopharmaceutical company’s stock worth $1,171,879,000 after acquiring an additional 5,572,451 shares during the period. AQR Capital Management LLC grew its stake in Pfizer by 120.9% in the 3rd quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock worth $230,986,000 after acquiring an additional 5,202,884 shares during the period. Finally, Voloridge Investment Management LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $105,709,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.